histamine dihydrochloride

Phase 3Small molecule

MMaxim Pharmaceuticals

histamine dihydrochloride is one of 151 small molecule programs targeting Kidney Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

150

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney CancerActive, not recruiting

MelanomaActive, not recruiting

Pancreatic CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Kidney CancerPhase 2

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

histamine dihydrochloride

MMaxim Pharmaceuticals

Phase 3

1 2

Gemzar

GGynecologic Oncology Group

Medrol

1 4

MS Contin

Merck & Co.

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

ABI-007

Bristol-Myers Squibb

Preclinical

2 7

LDE225

Novartis

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Thiazolidinediones

Sanofi

Preclinical

1 10

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Pancreatic Cancer

NCT05810792

Clinical

Trials by Indication[1]

Kidney Cancer1 trial

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer

Unknown status·TThe Christie NHS Foundation Trust·Phase 2·NCT00005038

Melanoma1 trial

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

Unknown status·MMaxim Pharmaceuticals·Phase 3·NCT00039234

Pancreatic Cancer1 trial

Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer

Not yet recruiting·SSahlgrenska University Hospital·Phase 2·NCT05810792·50 enrolled

Acute Myeloid Leukemia1 trial

Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia

Completed·MMaxim Pharmaceuticals·Phase 3·NCT00003991·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for histamine dihydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — histamine dihydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for histamine dihydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Maxim Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMaxim Pharmaceuticals

histamine dihydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Kidney Cancer1 trial

Melanoma1 trial

Pancreatic Cancer1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News